H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on IN8bio (INAB) to $8 from $12.50 and keeps a Buy rating on the shares post the Q3 report. The company is implementing strategies to de-risk INB-100 ahead of the registrational study, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio